(Q37731629)

22 August 2017

1 reference

title

Diabetes and weight management (English)

1 reference

22 August 2017

David C W Lau

1

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

published in

Primary Care Diabetes

1 reference

22 August 2017

volume

4 Suppl 1

1 reference

22 August 2017

page(s)

S24-30

1 reference

Obesity and diabetes in the developing world--a growing challenge

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Obesity and disease management: effects of weight loss on comorbid conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Intentional weight loss and mortality among overweight individuals with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Obesity, weight loss and prognosis in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Dietary treatment and long-term weight loss and maintenance in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Diabetes medications and body weight

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

How to achieve a predictable basal insulin?

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960006-X

7 January 2021

10.1016/S1751-9918(10)60006-X

Identifiers

DOI

1 reference

22 August 2017

1 reference